<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="122" ids="21241">Vitamin C</z:chebi>, available in its reduced form (<z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi>; AA) and in its oxidized form (<z:chebi fb="0" ids="17242,27956">dehydroascorbic acid</z:chebi>; DHA), may act in physiological conditions as an <z:chebi fb="11" ids="22586">antioxidant</z:chebi> or pro-oxidant </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study is to evaluate the cytotoxic effects of pharmacological doses of AA in a human colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell line (WiDr) in vitro, through spectrophotometry, clonogenic assays and flow cytometry, and in vivo with xenotransplanted Balb/c nu/nu mice </plain></SENT>
<SENT sid="2" pm="."><plain>The results show that the reduced form of <z:chebi fb="122" ids="21241">vitamin C</z:chebi> induces an anti-proliferative and cytotoxic effect in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> colorectal cells under study </plain></SENT>
<SENT sid="3" pm="."><plain>The results obtained in vivo after treatment with AA showed a large reduction in the rate of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Such understanding can guide decisions about which <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients might potentially benefit from <z:chebi fb="122" ids="21241">vitamin C</z:chebi> pharmacologic therapy </plain></SENT>
</text></document>